---
title: Validation of the PANAMA-Score for Survival and Benefit of Adjuvant Therapy
  in Patients with Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX
date: '2025-01-31'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39886770/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250131170637&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: The PANAMA 3-tier risk groups (low-risk, intermediate-risk,
  and high-risk, available via pancreascalculator.com) correspond with differential
  survival in patients with resected PDAC following neoadjuvant FOLFIRINOX. The risk
  groups also differentiate between survival benefit associated with adjuvant treatment,
  with only the intermediate- and high-risk groups associated with improved ...'
disable_comments: true
---
CONCLUSIONS: The PANAMA 3-tier risk groups (low-risk, intermediate-risk, and high-risk, available via pancreascalculator.com) correspond with differential survival in patients with resected PDAC following neoadjuvant FOLFIRINOX. The risk groups also differentiate between survival benefit associated with adjuvant treatment, with only the intermediate- and high-risk groups associated with improved ...